Skip to content

Study of the Diet in Patients With the Diagnostic of Acute Pancreatitis

Randomized Multicenter Prospective Clinical Trial to Compare the Effectiveness of Starting Early Oral Diet Versus Nil Per Oral in Patients With Acute Pancreatitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03829085
Acronym
PADI
Enrollment
120
Registered
2019-02-04
Start date
2017-06-01
Completion date
2018-12-31
Last updated
2019-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis, Acute

Keywords

Acute Pancreatitis, Oral refeeding, Nutrition, Length hospitalization

Brief summary

Acute pancreatitis (AP) is a common condition in emergency services worldwide. Approximately 85% of AP are mild and the patients usually recover within 1 to 2 weeks, not requeiring any critical care and organ support. The management of mild AP conventionally involves fasting, intravenous hydration and adequate analgesia until pain improves in order to prevent stimulation and allow the pancreas gland to rest. The current guidelines recommend the oral food intake should be tried as soon as possible, and beneficial effects or early enteral nutrition with mild AP have been reported in literature. Then, early oral refeeding (EORF) after mild and moderate AP is beneficial, but the optimal timing and starting criteria are unclear. Even now, refeeding after mild and moderate AP is typically started until clinical symptoms have resolved and pancreatic enzymes are decreasing, in a successively increasing manner. The aim of this study is to evaluate length of hospital stay, clinical findings and complications for EORF with immediately full caloric intake in patients with mild and moderate AP.

Detailed description

This is prospective, randomized, controlled, multicentre trial. Patients with mild and moderate acute pancreatitis (AP) will be randomly in two groups: group A: with early oral refeeding (EOR) with low fat solid diet (LFSD), started from the first day of admission in the hospital, and group B: with Nil Per Oral (NPO), until the symptoms, signs, inflammatory parameters of AP have resolved. The primary and several secondary endpoints will be obtained and EORF with LFSD will improve the following measures of outcome: 1. Length of hospital admission (the primary endpoint) 2. Serum amylase, lipase, electrolytes, calcium, urea, creatinine, liver function tests, C-reactive protein (biomarker of inflammation), nutritional parameters (albumin, prealbumin, cholesterol, triglycerides) and full blood count - routine blood tests performed daily until normalization of serum lipase or until discharge. 3. Weight, at hospital admission and discharge, and at day 30 post-discharge clinic follow-up. 4. Systemic complications including hemodynamic instability, renal failure, intensive care admission, surgery, radiological and endoscopic procedures. 5. Pain and Analgesic requirement. 6. Local complications including pancreatic necrosis, abscess, pseudocyst.

Interventions

the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day

Sponsors

Hospital Universitari Joan XXIII de Tarragona.
CollaboratorOTHER
Hospital Clinic of Barcelona
CollaboratorOTHER
Consorci Sanitari del Garraf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* 1\) Diagnosed of AP by at least two of these three criteria: compatible abdominal pain, amylase or lipase level superior in three-fold respective laboratory baseline levels, and suitable findings in imaging techniques (CT, ultrasound or MRI) * 2\) age \> 18 years, sign consent form.

Exclusion criteria

* 1\) pregnant o breastfeeding women; * 2\) abdominal pain lasting \>96 horas before admission; * 3\) the possibility of poor oral intake for reasons other than AP; * 4\) Pancreatic neoplasm, endoscopic retrograde cholangiopancreatography or trauma etiology; * 5\) Chronic pancreatitis; * 6\) Randomization greater the 12 hours after admission

Design outcomes

Primary

MeasureTime frameDescription
Length of hospitalizationmeasured from onset of admission until time of actual discharge from hospital. Assessed between 1-10 days up to 14 days.Days

Secondary

MeasureTime frameDescription
Duration of fasting2-3 days approximately since the first day of hospital admissionDays
Tolerance to food2-7 days approximately during hospital admission and during the follow upThe patient's symptoms are controlled with the established treatment and the patient can eat at least 50% of the meals
Elevation of serum amylase or lipase2-4 days approximately during hospital admission after oral refeeding, until hospital dischargeElevation amylase or lipase level after oral refeeding
Relapse of abdominal painmeasured from onset of admission until time of actual discharge from hospital. Assessed between 1-10 days up to 14 days, and during the follow up (1 month after discharge)Pain Scale: 0=No pain, 1=Very mild, 2=Discomforting, 3=Tolerable, 4=Distressing, 5=Distressing, 6=Intense pain, 7=Very intense pain, 8=Horrible pain, 9=Excruciating, 10=Unimaginable pain
DeathDuring hospital stay (up to 1 day)Mortality
Operation rate2 monthThe rate of patients received operation for pancreatitis debridement
Intra-abdominal infection1 monthFever: temperature greater than 38 or positive cultures of blood or pancreatic necrosis

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026